These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 22892261)

  • 1. Late toxicity rates following definitive radiotherapy for prostate cancer.
    Ohri N; Dicker AP; Showalter TN
    Can J Urol; 2012 Aug; 19(4):6373-80. PubMed ID: 22892261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.
    Kalakota K; Liauw SL
    Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
    Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Commentary on "Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus." Kalakota K, Liauw SL, Department of Radiation Oncology, Northwestern Memorial Hospital, Chicago, IL.: Urology 2013;81(6):1196-201. doi: 10.1016/j.urology.2013.01.047. [Epub 2013 Mar 26].
    Gottschalk A
    Urol Oncol; 2014 Apr; 32(3):374. PubMed ID: 24679464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients.
    Lips IM; Dehnad H; van Gils CH; Boeken Kruger AE; van der Heide UA; van Vulpen M
    Radiat Oncol; 2008 May; 3():15. PubMed ID: 18495016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy.
    Sutani S; Ohashi T; Sakayori M; Kaneda T; Yamashita S; Momma T; Hanada T; Shiraishi Y; Fukada J; Oya M; Shigematsu N
    Radiother Oncol; 2015 Nov; 117(2):270-6. PubMed ID: 26318662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields.
    Jani AB; Su A; Correa D; Gratzle J
    Prostate Cancer Prostatic Dis; 2007; 10(1):82-6. PubMed ID: 16983394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts.
    Wortel RC; Incrocci L; Pos FJ; van der Heide UA; Lebesque JV; Aluwini S; Witte MG; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):680-9. PubMed ID: 27055398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer.
    Liauw SL; Weichselbaum RR; Rash C; Correa D; Al-Hallaq HA; Pelizzari CA; Jani AB
    Technol Cancer Res Treat; 2009 Jun; 8(3):201-6. PubMed ID: 19445537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
    Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
    Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.
    Adkison JB; McHaffie DR; Bentzen SM; Patel RR; Khuntia D; Petereit DG; Hong TS; Tomé W; Ritter MA
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):184-90. PubMed ID: 21163590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
    Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.
    Fang P; Mick R; Deville C; Both S; Bekelman JE; Christodouleas JP; Guzzo TJ; Tochner Z; Hahn SM; Vapiwala N
    Cancer; 2015 Apr; 121(7):1118-27. PubMed ID: 25423899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
    Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer.
    Nath SK; Sandhu AP; Rose BS; Simpson DR; Nobiensky PD; Wang JZ; Millard F; Kane CJ; Parsons JK; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):435-41. PubMed ID: 19939580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer.
    Al-Mamgani A; Heemsbergen WD; Peeters ST; Lebesque JV
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):685-91. PubMed ID: 18718725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of intensity-modulated radiotherapy on acute genitourinary and gastrointestinal toxicity in the treatment of localized prostate cancer.
    Jani AB; Gratzle J; Correa D
    Technol Cancer Res Treat; 2007 Feb; 6(1):11-5. PubMed ID: 17241095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.